NCT07511933Recruiting
Novel Ga68-PSMA PET/CT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Brain Metastases
Novel Ga68-PSMA PET/CT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Stereotactic Irradiated Brain Metastases: a Feasibility Study
Source: ClinicalTrials.gov · Last updated 24 Jul 2026
Brief summary (registry, in English)
This study aims to evaluate the diagnostic potential of 68-Gallium PSMA-PET/CT in stereotactic irradiated brain metastases from non-small cell lung cancer, melanoma and breast cancer.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 30 Mar 2026
- Start date
- 24 Dec 2019
- Primary completion date
- 1 Jan 2027
- Lead sponsor
- The Netherlands Cancer Institute
- Diseases
- Melanoma, Lung cancer, Childhood cancers
- NCT number
- NCT07511933
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 24 Dec 2019 to the primary completion date, 1 Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Epileptic seizure less than 7 days before Ga68-PSMA PET/CT scan
Other illness
- Known allergy to Ga68-PSMA
Other
- For all groups:
- Life expectancy less than 3 months
- Patients with known prostate carcinoma
- Pregnancy
Who the study is looking for
- For all groups:
- Written informed consent
- Age ≥ 18 years old
- WHO PS 0-3
- Measurable lesion ≥10mm according to RANO BM
- For brain metastases groups:
- \- newly diagnosed brain metastases from either NSCLC (group 1) or melanoma (group 2) or breast cancer (group 7).
- For radiation necrosis groups:
- \- Brain lesion at the location of a formerly brain metastases that has been treated with SRT (\> 9 months ago), with the definite diagnosis of radiation necrosis at the location of formerly SRT-treated brain metastases of NSCLC (group 3), melanoma (group 4) and/ or breast cancer (group 8).
- For diagnostic dilemma groups:
- \- Brain lesion at the location of a formerly brain metastases with a diagnostic dilemma of radiation necrosis and recurrent brain metastases of NSCLC (group 5), melanoma (group 6) and/ or breast cancer (group 9).
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Netherlands Cancer Institute-Antoni van Leeuwenhoek Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.